在心力衰竭患者中,levosimendan对血肠道屏障因子的影响,这些患者的排泄分数减少
Youxuan Wu1,2, Xiaolei Hu3, Xiaoxiao Mao4
1Phase Ⅰ Clinical Trial Center, Xiangya Hospital, Central South University, Changsha 410008. w18896733270@163.com.
概括
在心力衰竭 (HF) 患者中,Levosimendan 治疗通过减少肠道屏障因素和调节炎性细胞因子,改善了肠道屏障功能. 这表明对与HF相关的胃肠道问题有潜在的治疗益处.
科学领域:
- 心脏病学 心脏病学
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 胃肠道不适是心力衰竭 (HF) 患者的常见并发症,通常源于肠道粘膜输液减少和肠道屏障功能受损.
- 利沃西门丹是一种积极的内类药物,增强心脏功能和全身循环,可能有利于肠道血液动力学.
- 对levosimendan对HF患者肠道屏障的保护作用及其潜在机制的临床证据有限.
研究的目的:
- 调查levosimendan对肠道屏障的保护作用,在心力衰竭急性恶化和减少喷射率 (HFrEF) 的患者中.
- 探索levosimendan可能改善HF患者肠道屏障功能的潜在机制.
主要方法:
- 网络药理学被用来预测levosimendan.com的潜在机制.
- 进行了一项临床试验,涉及62名住院的HFrEF患者,将传统治疗组 (n=31) 与levosimendan治疗组 (n=31) 进行比较.
- 使用ELISA测量了肠道屏障蛋白 (松素,I-FABP),炎症性细胞因子 (IL-17,IL-6,TNF-α),抗炎性细胞因子 (IL-10) 和NT-proBNP的血水平. 用KCCQ和GSRS评估心脏功能和胃肠道症状.
主要成果:
- 网络药理学表明,levosimendan的影响涉及与炎症相关的途径 (IL-17,TNF).
- 与常规组相比,levosimendan组显示佐努林,I-FABP,IL-6,IL-17和TNF-α的显著减少. 在levosimendan组,IL-10显著增加.
- 虽然KCCQ和GSRS得分显示了levosimendan组的改善趋势,但这些差异在统计学上并不显著.
结论:
- 莱沃西门丹改善了HFrEF患者急性恶化时的肠道屏障功能,由降低的血肠道屏障因子证明.
- 这些改善与炎症状况的调节有关,包括减少的促炎细胞因子和增加的抗炎细胞因子.
- 潜在的机制可能涉及IL-17和TNF信号通路,这表明levosimendan有潜力缓解与HF相关的胃肠道症状.
相关概念视频
01:22Heart Failure Drugs: Diuretics
789
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
789
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
01:30Heart Failure V: Medical Management
209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209
01:29Heart Failure II: Pathophysiology
704
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
704
01:22Heart Failure Drugs: β-Blockers
758
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
758